Johnson & Johnson
Johnson & Johnson Announces Retirement of Chief Human Resources Officer
Summary
Johnson & Johnson announced on August 26, 2024, that Peter M. Fasolo, Executive Vice President and Chief Human Resources Officer (CHRO), will retire at the end of the year. Kristen Mulholland will succeed Fasolo as CHRO, effective October 1, 2024. Fasolo, who has been with the company for 16 years, has been instrumental in shaping the company's human capital strategy and will work with Mulholland during the transition period.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement